Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo 20 or 60 mg

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,778 result(s) found for: Placebo 20 or 60 mg. Displaying page 1 of 89.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-004960-64 Sponsor Protocol Number: F1J-MC-HMDW(b) Start Date*: 2005-05-13
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
    Medical condition: Generalised Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001440-23 Sponsor Protocol Number: Protocol CRx-139-003 Start Date*: 2005-09-22
    Sponsor Name:CombinatoRx, Inc.
    Full Title: A SINGLE CENTER, BLINDED, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE EFFECT OF CRx-139 ON POCKET DEPTH AND INFLAMMATORY CYTOKINES COMPARED TO PLACEBO IN SUBJECTS WITH SEVERE ADULT PERIODONTITIS
    Medical condition: SEVERE ADULT PERIODONTITIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003723-29 Sponsor Protocol Number: JBT101-CF-002 Start Date*: 2018-05-11
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000932-25 Sponsor Protocol Number: DS107G-05-AD3 Start Date*: 2019-07-25
    Sponsor Name:DS Biopharma Ltd.
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001518-26 Sponsor Protocol Number: DFI10569 Start Date*: 2009-03-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Efficacy and safety of oral ataciguat (HMR1766) 200 mg administered once daily for 28 days on pain reduction in patients with Neuropathic Pain. A randomized, double-blind, placebo-controlled, cross...
    Medical condition: The proposed study is planned to demonstrate that ataciguat 200 mg/day could be effective in reducing neuropathic pain with a good safety profile
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005056-96 Sponsor Protocol Number: TRAWADA2015 Start Date*: 2016-05-31
    Sponsor Name:Daniel Sanabria Lucena
    Full Title: Use of tramadol in healthy volunteers. Effects on physical performance and sustained attention in cycling.
    Medical condition: Sport doping
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10076471 Drug doping LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002089-42 Sponsor Protocol Number: R1908-1909-ALG-2102 Start Date*: 2021-11-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural ...
    Medical condition: Allergic Rhino conjunctivitis due to Cat Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000314-12 Sponsor Protocol Number: SC2-90049-003 Start Date*: 2005-10-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-...
    Medical condition: Parkinson's Disease aggravated
    Disease: Version SOC Term Classification Code Term Level
    7.0 10034006 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001131-30 Sponsor Protocol Number: EZ-2053-001 Start Date*: 2005-07-22
    Sponsor Name:Fresenius Biotech North America
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter, Dose-ranging Study of an Anti-T-lymphocyte Immunglobuline (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of...
    Medical condition: Patients with end-stage pulmonary failure, who are receiving a primary single or double pulmonary allograft
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002976-28 Sponsor Protocol Number: CCNP520A2202J Start Date*: 2017-05-16
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease ...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FI (Prematurely Ended) IS (Completed) PT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004701-40 Sponsor Protocol Number: TOOL Start Date*: 2018-08-06
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A PILOT, PHASE II STUDY WITH A PROSPECTIVE, RANDOMIZED, CROSS-OVER, PLACEBO-CONTROLLED, DOUBLE-BLIND DESIGN TO ASSESS THE SHORT-TERM EFFECTS OF TOLVAPTAN PLUS PLACEBO VS TOLVAPTAN PLUS OCTREOTIDE ...
    Medical condition: Autosomal Dominant Policiytic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002083-27 Sponsor Protocol Number: KAD169 Start Date*: 2012-10-29
    Sponsor Name:Dr. Kade Pharmazeutische Fabrik GmbH
    Full Title: Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine 60 mg/suppository in abatement of complaints associated with hemorrhoids
    Medical condition: Relief of complaints associated with hemorrhoids (pain, burning, itching)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10002580 Anorectal therapeutic procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019414-24 Sponsor Protocol Number: GA0921 Start Date*: 2010-07-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single centre, randomised, partially-blind, placebo-controlled 3 way crossover pilot study investigating efficacy in terms of heartburn relief after taking (2x250mg) Gaviscon® chewable tablets...
    Medical condition: Investigating efficacy in terms of heatburn relief in healthy subjects following a refluxogenic meal.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014810-87 Sponsor Protocol Number: CL2-NEURO-005 Start Date*: 2010-07-22
    Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
    Full Title: Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients sufferi...
    Medical condition: - Patients suffering from Mild Cognitive Impairment (memory problems, objective memory disorder, absence of other cognitive disorders or repercussions on daily life, normal general cognitive functi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005458-97 Sponsor Protocol Number: VAC18193RSV3001 Start Date*: 2021-10-28
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years an...
    Medical condition: Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003448-58 Sponsor Protocol Number: 3101-304-002 Start Date*: 2021-02-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Pa...
    Medical condition: Episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004852 10082019 Episodic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed) HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002690-29 Sponsor Protocol Number: CVAY736F12302 Start Date*: 2023-06-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupu...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004048-50 Sponsor Protocol Number: 3-062-18 Start Date*: 2019-02-14
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian
    Full Title: Double blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP)
    Medical condition: Sleep disturbance in patients with chronic pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10040995 Sleep disturbance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-002844-24 Sponsor Protocol Number: H6D-MC-LVGX Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Double-Blind, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001480-42 Sponsor Protocol Number: MIPO3801011 Start Date*: 2012-04-26
    Sponsor Name:Genzyme Corporation and its Affiliates
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemi...
    Medical condition: Heterozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) BE (Completed) GB (Completed) FR (Completed) HU (Completed) DE (Completed) CZ (Completed) GR (Completed) IT (Completed) PL (Completed) SK (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 10:08:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA